



Patent Application  
Attorney Docket No. PC26098A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents P. O. Box 1450, Alexandria, VA 22313-1450 on this 19th day of April 2004

By

*Irene Grantham*

(Signature of person mailing)  
Irene Grantham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Charles Price Tayler, Jr, et al.

APPLICATION NO.: 10/726,878 : Examiner: To Be Assigned

FILING DATE: December 2, 2003 : Group Art Unit: 1614

TITLE: METHOD OF TREATMENT FOR SEXUAL :  
DYSFUNCTION

Hon. Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: April 16, 2004  
Pfizer Inc.  
Patent Department, MS 8260-1611  
Eastern Point Road  
Groton, Connecticut 06340  
(860) 715-4288

Martha G. Munchhof  
Martha G. Munchhof  
Attorney for Applicant(s)  
Reg. No. 47,811



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC26098A	SERIAL NO. 10/726,878
	APPLICANT Charles Price Tayler, Jr.	
	FILING DATE December 2, 2003	GROUP 1614

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
/R.H./	US 2003 1 9 5 2 5 1	10/16/03	Barta, et al.	514	561	
	US 2 5 0 3 0 5 9	4/4/50	Miescher, et al.	260	309.6	
	US 2 5 9 9 0 0 0	6/3/52	Kerwin, et al.	260	570.7	
	US 3 3 8 1 0 0 9	4/30/68	Palazzo, et al.	260	268	
	US 3 5 1 1 8 3 6	5/12/70	Hess	260	256.4	
	US 3 9 2 7 7 6 1	9/8/70	Archibald, et al.	260	250	
	US 3 9 9 7 9 6 6	12/14/76	Witte, et al.	424	250	
	US 7 0 2 7 7 7 1	5/17/77	Satzinger, et al.	260	468J	
	US 7 0 2 6 3 6 1	5/31/77	Winn, et al.	260	256.4Q	
	US 7 1 3 3 9 6 1	4/12/80	Campbell	424	250	
	US 4 2 3 2 7 2 1	2/24/81	Silvestrini, et al.	260	243.3	
	US 4 3 1 5 5 2 7	2/9/82	Manoury	424	251	
	US 7 1 3 3 9 6 3	10/27/87	Imai, et al.	514	603	
✓	US 3 9 2 3 1 2 6	10/8/96	Silverman, et al.	514	561	
/R.H./	US 3 9 7 3 7 7 1	8/31/99	El-Rashidy, et al.	424	430	

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
/R.H./	WO 9 1 1 1 1 7 2	8/8/91	PCT	A61K	9/00		
	WO 9 4 0 2 5 1 8	2/3/94	PCT	C08B	37/16		
	WO 9 7 2 9 1 0 1	8/14/97	PCT	C07D	309/04		
	WO 9 7 3 3 8 5 8	9/18/97	PCT	C07C	229/28		
	WO 9 7 3 3 8 5 9	9/18/97	PCT	C07C	229/28		
	WO 9 8 1 7 6 2 7	4/30/98	PCT	C07C	229/22		
	WO 9 8 5 5 1 4 8	12/10/98	PCT	A61K	47/48		
✓	WO 9 9 2 1 8 2 4	5/6/99	PCT	C07C	229/28		
/R.H./	WO 9 9 3 0 6 9 7	8/24/99	PCT	A61K	31/00		



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)										ATTY. DOCKET NO. PC26098A		SERIAL NO. 10/726,878		
										APPLICANT Charles Price Tayler, Jr.				
										FILING DATE December 2, 2003		GROUP 1614		
/R.H./	WO	9	9	3	1	0	5	7	6/24/99	PCT	C07D	211/26		
	WO	9	9	3	1	0	7	4	6/24/99	PCT	C07D	257/00		
	WO	9	9	3	1	0	7	5	6/24/99	PCT	C07D	257/04		
	WO	0	0	6	1	1	3	5	10/19/00	PCT	A61K	31/197		
	WO	0	0	7	6	9	5	8	12/21/00	PCT	C07C	229/08		
	WO	0	1	2	8	9	7	8	4/26/01	PCT	C07C	229/28		
	WO	0	2	6	8	3	4		10/31/02	PCT	C07C	229/28		
	WO	02	1	0	0	8	4	7	12/19/02	PCT	A61K			
	WO	02	1	0	0	3	9	0	12/19/02	PCT	A61K	31/195		
	WO	0	2	2	2	0	9	9	3/21/02	PCT	C07C	323/58		
	WO	0	2	0	8	2	4	4	4/11/02	PCT	C07J	5/00		
	WO	0	2	3	2	0	4	0	4/18/02	PCT	C07C	229/08		
	WO	0	2	3	2	2	4	4	4/18/02	PCT	C07C	311/64		
	WO	0	2	0	2	3	4	4	5/30/02	PCT	C12N			
	WO	0	3	0	2	2	0	0	1/3/03	PCT	C07C	203/04		
	WO	0	3	0	2	2	0	4	10/9/03	PCT	C07C	229/08		
	EP	0	0	0	1	3	0	0	10/17/01	EP	C07C	229/00		
	EP	0	2	3	1	0	9	4	5/28/03	EP	A61K	31/195		
✓	EP	0	0	0	0	0	4	7	2/6/02	EP	C07C	233/63		
/R.H./	EP	0	2	0	3	2	4	0	5/2/02	EP	A61K	31/41		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>														
/R.H./	Gee, et al., "The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the $\alpha_2\delta$ Subunit of a Calcium Channel", <u>The Journal of Biological Chemistry</u> 271(10), pp. 5768-5776 (1996)													
/R.H./	Williams, et al., "1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo[2.2.1]heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine (L-368,899): An Orally Bioavailable, Non-Peptide Oxytocin Antagonist with Potential Utility for Managing Preterm Labor", <u>J. Med. Chem.</u> 37, pp. 565-571 (1994)													
/R.H./	Yonezawa, et al., "Characterization of p-chloroamphetamine-induced penile erection and ejaculation in anesthetized rats", <u>Life Sciences</u> 67, pp. 3031-3039 (2000)													
/R.H./	Tamkai, et al., "Synthesis of 4-cis-Phenyl-L-proline via Hydrogenolysis", <u>J. Org. Chem.</u> 66, pp. 3593-3596 (2001)													
/R.H./	The Merck Manual, 6th Edition, "Orgasm Disorders", pp. 1576-1577, by Merck Research Laboratories (1992)													
EXAMINER	/Raymond J. Henley III/										DATE CONSIDERED			May 28, 2008

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	ATTY. DOCKET NO. PC26098A	SERIAL NO. 10/726,878
	APPLICANT Charles Price Tayler, Jr.	
	FILING DATE December 2, 2003	GROUP 1614
/Raymond J Henley III/ May 28, 2008		
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE